CA3244313A1 - Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer - Google Patents

Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer

Info

Publication number
CA3244313A1
CA3244313A1 CA3244313A CA3244313A CA3244313A1 CA 3244313 A1 CA3244313 A1 CA 3244313A1 CA 3244313 A CA3244313 A CA 3244313A CA 3244313 A CA3244313 A CA 3244313A CA 3244313 A1 CA3244313 A1 CA 3244313A1
Authority
CA
Canada
Prior art keywords
regorafenib
inhibitors
combination
treating cancer
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3244313A
Other languages
English (en)
Inventor
Sabine HOFF
Lars Rose
Dieter Zopf
Fabian Kiessling
Wiltrud LEDERLE
Dennis DOLESCHEL
Original Assignee
Bayer Healthcare LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare LLC filed Critical Bayer Healthcare LLC
Publication of CA3244313A1 publication Critical patent/CA3244313A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
CA3244313A 2017-06-02 2018-05-25 Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer Pending CA3244313A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17174169 2017-06-02
EP17174169.7 2017-06-02

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA3065125A Division CA3065125C (en) 2017-06-02 2018-05-25 COMBINATION OF REGORAFENIB AND PD-1/PD-L1 INHIBITORS(2) FOR THE TREATMENT OF CANCER

Publications (1)

Publication Number Publication Date
CA3244313A1 true CA3244313A1 (en) 2025-06-13

Family

ID=58992733

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3244313A Pending CA3244313A1 (en) 2017-06-02 2018-05-25 Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer
CA3065125A Active CA3065125C (en) 2017-06-02 2018-05-25 COMBINATION OF REGORAFENIB AND PD-1/PD-L1 INHIBITORS(2) FOR THE TREATMENT OF CANCER

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3065125A Active CA3065125C (en) 2017-06-02 2018-05-25 COMBINATION OF REGORAFENIB AND PD-1/PD-L1 INHIBITORS(2) FOR THE TREATMENT OF CANCER

Country Status (22)

Country Link
US (4) US11951166B2 (enExample)
EP (2) EP4342542A3 (enExample)
JP (3) JP7303122B2 (enExample)
KR (2) KR102673422B1 (enExample)
CN (3) CN110662540B (enExample)
AU (2) AU2018276273B2 (enExample)
BR (1) BR112019025478A8 (enExample)
CA (2) CA3244313A1 (enExample)
DK (1) DK3630112T3 (enExample)
ES (1) ES2978337T3 (enExample)
FI (1) FI3630112T3 (enExample)
HR (1) HRP20240551T1 (enExample)
HU (1) HUE066487T2 (enExample)
IL (2) IL270948B2 (enExample)
LT (1) LT3630112T (enExample)
MX (1) MX2023001721A (enExample)
PE (2) PE20200859A1 (enExample)
PL (1) PL3630112T3 (enExample)
PT (1) PT3630112T (enExample)
RS (1) RS65488B9 (enExample)
SI (1) SI3630112T1 (enExample)
WO (1) WO2018219807A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL270948B2 (en) * 2017-06-02 2025-07-01 Bayer Ag Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer
CN111001004A (zh) * 2019-10-08 2020-04-14 广州医科大学附属第二医院 一种治疗肝癌的药物组合及其应用
WO2025117638A1 (en) * 2023-12-01 2025-06-05 Yale University Compositions and methods for treating cancer

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102816113B (zh) 2003-07-23 2015-05-13 拜耳医药保健有限责任公司 用于治疗和预防疾病和疾病症状的氟代ω-羧芳基二苯基脲
WO2007054303A2 (en) 2005-11-10 2007-05-18 Bayer Healthcare Ag Diaryl urea for treating diabetic neuropathy
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
JO3479B1 (ar) * 2012-09-06 2020-07-05 Bayer Healthcare Llc تركيبة دوائية مغلفة تحتوي على ريجورافنيب
MY183969A (en) * 2012-09-25 2021-03-17 Bayer Pharma AG Combination of regorafenib and acetylsalicylic acid for treating cancer
JP5653489B1 (ja) 2013-07-24 2015-01-14 三菱エンジニアリングプラスチックス株式会社 薄肉光学部材用ポリカーボネート樹脂ペレット及びその製造方法
PT3102605T (pt) 2014-02-04 2019-02-12 Pfizer Combinação de um antagonista da mp-1 e um inibidor do rfcev para o tratamento do cancro
EP3338801A1 (en) 2014-02-21 2018-06-27 Idac Theranostics, Inc. Therapeutic agent for solid cancer
CA2955177A1 (en) 2014-07-15 2016-01-21 The Johns Hopkins University Suppression of myeloid derived suppressor cells and immune checkpoint blockade
WO2016011160A1 (en) 2014-07-15 2016-01-21 Genentech, Inc. Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
US10392444B2 (en) * 2014-08-08 2019-08-27 Oncoquest, Inc. Tumor antigen specific antibodies and TLR3 stimulation to enhance the performance of checkpoint interference therapy of cancer
CA2958573A1 (en) * 2014-08-19 2016-02-25 National University Corporation Okayama University Agent for treating and/or preventing diseases associated with immune abnormalities by combining biguanide antidiabetic drug with immunosuppressive factor blocking agent or costimulatory receptor agonist
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
CN106999582A (zh) 2014-11-13 2017-08-01 约翰·霍普金斯大学 检查点阻断和微卫星不稳定性
WO2016173959A1 (en) * 2015-04-28 2016-11-03 Bayer Pharma Aktiengesellschaft Regorafenib for treating colorectal cancer
WO2017046746A1 (en) 2015-09-15 2017-03-23 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
JP2019517507A (ja) 2016-06-03 2019-06-24 イムクローン リミテッド ライアビリティ カンパニー 特定の癌の治療のためのラムシルマブとペンブロリズマブとの組み合わせ
US10251888B2 (en) 2016-06-13 2019-04-09 Chemocentryx, Inc. Method of treating pancreatic cancer
IL270948B2 (en) * 2017-06-02 2025-07-01 Bayer Ag Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer
MX2019014577A (es) * 2017-06-05 2020-07-29 Janssen Biotech Inc Anticuerpos que se unen especificamente a pd-1 y metodos de uso.

Also Published As

Publication number Publication date
RU2019143599A3 (enExample) 2021-09-10
SI3630112T1 (sl) 2024-06-28
FI3630112T3 (fi) 2024-05-02
IL270948B1 (en) 2025-03-01
BR112019025478A8 (pt) 2022-12-06
IL317015A (en) 2025-01-01
US20200188372A1 (en) 2020-06-18
PL3630112T3 (pl) 2024-07-01
PT3630112T (pt) 2024-04-23
US20200179354A1 (en) 2020-06-11
EP4342542A2 (en) 2024-03-27
AU2018276273A1 (en) 2019-12-12
AU2018276273B2 (en) 2023-12-21
JP7475402B2 (ja) 2024-04-26
US20220133888A1 (en) 2022-05-05
US11951166B2 (en) 2024-04-09
ES2978337T3 (es) 2024-09-10
LT3630112T (lt) 2024-05-10
EP3630112B1 (en) 2024-01-31
AU2023282197A1 (en) 2024-01-04
RS65488B1 (sr) 2024-05-31
CN110662540B (zh) 2024-01-26
PE20200859A1 (es) 2020-08-25
AU2023282197B2 (en) 2025-06-26
EP4342542A3 (en) 2024-06-05
EP3630112B9 (en) 2024-06-26
DK3630112T3 (da) 2024-04-22
CA3065125A1 (en) 2018-12-06
JP7303122B2 (ja) 2023-07-04
KR20240091188A (ko) 2024-06-21
CA3065125C (en) 2025-06-10
EP3630112A1 (en) 2020-04-08
CN117899212A (zh) 2024-04-19
US20200155674A1 (en) 2020-05-21
US11517622B2 (en) 2022-12-06
WO2018219807A1 (en) 2018-12-06
KR20200011971A (ko) 2020-02-04
MX2023001721A (es) 2023-02-22
JP2020521786A (ja) 2020-07-27
CN117582495A (zh) 2024-02-23
KR102843438B1 (ko) 2025-08-06
JP2024096905A (ja) 2024-07-17
HRP20240551T1 (hr) 2024-07-05
IL270948A (en) 2020-01-30
KR102673422B1 (ko) 2024-06-07
CN110662540A (zh) 2020-01-07
IL270948B2 (en) 2025-07-01
JP2022169780A (ja) 2022-11-09
HUE066487T2 (hu) 2024-08-28
BR112019025478A2 (pt) 2020-06-23
RS65488B9 (sr) 2024-09-30
PE20242220A1 (es) 2024-11-19
RU2019143599A (ru) 2021-07-09

Similar Documents

Publication Publication Date Title
PH12021500004A1 (en) Pd-1/pd-l1 inhibitors
EP4026835A3 (en) Pd-1/pd-l1 inhibitors
IL263178A (en) Fidi-1 / Fidi-AL1 inhibitors for cancer treatment
IL254131A0 (en) Fidi-1 / Fidi-AL1 inhibitors for cancer treatment
EP3938354A4 (en) COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER
EP3843711A4 (en) METHODS OF CANCER TREATMENT WITH SMALL MOLECULE PD-L1 INHIBITORS
SG11202010423VA (en) COMBINED INHIBITION OF PD-1/PD-L1, TGFß AND DNA-PK FOR THE TREATMENT OF CANCER
EP3630080A4 (en) USE OF EZH2 INHIBITORS TO TREAT CANCER
EP3968785A4 (en) COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER
CA3244313A1 (en) Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer
EP3773585A4 (en) Compositions and methods for treating cancer
EP3714043A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER
EP4077690A4 (en) METHODS AND COMPOSITIONS FOR TREATING CANCER
EP3989985A4 (en) METHODS AND COMPOSITIONS FOR TREATING PANCREATIC CANCER
HK40109111A (zh) 用於治疗癌症的瑞格菲尼和pd-1/pd-l1(2)抑制剂的组合产品
HK40105741A (zh) 用於治疗癌症的瑞格菲尼和pd-1/pd-l1(2)抑制剂的组合产品
HK40061677A (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
HK40047083A (en) Combination of lif inhibitors and pd-1 axis inhibitors for use in treating cancer
HK40079012A (en) Methods and compositions for treating cancer
HK40055593A (en) Methods of treating cancer with small molecule pd-l1 inhibitors
HK40059427A (en) Administration of pd-1 inhibitors for treating skin cancer
HK40072464A (en) Compositions and methods for treating cancer
HK40071110A (en) Compositions and methods for treatment of cancer
HK40064863A (en) Compositions and methods for treating cancer
HK40067803A (en) Methods and compositions for treating cancer